Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Korean Med Sci ; 38(48): e382, 2023 Dec 11.
Article in English | MEDLINE | ID: mdl-38084026

ABSTRACT

The current emergence of the coronavirus disease 2019 (COVID-19) pandemic and the possible side effects of COVID-19 mRNA vaccination remain worrisome. Few cases of vaccination-related side effects, such as vasculitis, have been reported. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a type of vasculitis characterized by the histological richness of eosinophils, asthma, polyneuropathy, sinusitis, and skin or lung involvement. Here, we report the first case of new onset EGPA following COVID-19 vaccination in Korea. A 71-year old woman developed a skin rash and presented with progressive weakness of the upper and lower extremities after the BNT162b2 vaccination (Pfizer-BioNTech). She was diagnosed with EGPA and her symptoms improved after systemic steroid and immunosuppressant therapy. Although it is very rare, clinicians should be aware that EGPA may occur after COVID-19 vaccination.


Subject(s)
COVID-19 Vaccines , COVID-19 , Churg-Strauss Syndrome , Granulomatosis with Polyangiitis , Aged , Female , Humans , BNT162 Vaccine , Churg-Strauss Syndrome/diagnosis , Churg-Strauss Syndrome/etiology , Churg-Strauss Syndrome/drug therapy , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Granulomatosis with Polyangiitis/diagnosis , Granulomatosis with Polyangiitis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...